Katy Barglow, PhD, is the CTO of 4D Molecular Therapeutics. Katy is biotechnology leader with a proven track record of advancing gene therapy manufacturing from concept to commercial readiness. Since joining 4D Molecular Therapeutics (4DMT) in 2017, she has built and scaled the company’s AAV production and analytical capabilities from the ground up. Under her leadership, the Chemistry, Manufacturing, and Controls (CMC) organization has successfully supported six IND filings, guided programs through early and late-phase clinical development, and positioned 4DMT for commercial launch. 
 
Her career spans senior roles at Baxter Biosciences, Novartis, and Grifols Diagnostics, where she honed expertise in biologics manufacturing, analytical development, and operational leadership. Katy holds a B.S. in Chemistry from Stanford University, a PhD in Chemical Biology from The Scripps Research Institute, and completed postdoctoral training at UC Berkeley.